Literature DB >> 27446285

Risk factors for symptomatic osteonecrosis in childhood ALL: A retrospective study of a Slovenian pediatric ALL population between 1970 and 2004.

Nataša Karas-Kuželički1, Simona Mencej-Bedrač1, Janez Jazbec2, Janja Marc1, Irena Mlinarič-Raščan1.   

Abstract

Treatment induced non-traumatic osteonecrosis (ON) has been reported increasingly in children treated for acute lymphoblastic leukemia (ALL). Several risk factors for ON have been identified in childhood cancer patients; however, their diagnostic and prognostic power is limited and the etiology of the disease remains unclear. Therefore, a continuous effort is focused on the identification of additional ON risk factors. We performed a retrospective study of 313 childhood ALL patients to test the association between the ON occurrence in children receiving ALL therapy and common polymorphisms in potential target genes: Thiopurine S-methyltransferase (TPMT; 460G>A, 719A>G), 5,10-methylenetetrahydrofolate reductase (MTHFR; 677C>T, 1298A>C), estrogen receptor alpha 1 (ESR1; XbaI) and collagen type I, α1 (COL1A1; Sp1). In the present cohort, higher age and more recently developed treatment protocols were independent risk factors for ON. In children >14.5 years old, TPMT genotype modulated the risk of ON. Additionally, in children <12.9 years old ESR1 genotypes were also implicated in the pathogenesis of ON. Besides greater age and more recent treatment protocols, genetic factors (polymorphisms in ESR1 and TPMT genes) were suggested to be implicated in the pathogenesis of ON and could be potentially used as genetic prognostic markers for ON.

Entities:  

Keywords:  5,10-methylenetetrahydrofolate reductase; acute lymphoblastic leukemia; collagen; estrogen receptor alpha 1; osteonecrosis; thiopurine S-methyltransferase; type I; α1

Year:  2016        PMID: 27446285      PMCID: PMC4950129          DOI: 10.3892/etm.2016.3391

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  42 in total

1.  The 677C-->T mutation of the methylene-tetrahydrofolate reductase gene in the pathogenesis of osteonecrosis of the femoral head.

Authors:  Charalampos G Zalavras; Konstantinos N Malizos; Eleni Dokou; George Vartholomatos
Journal:  Haematologica       Date:  2002-01       Impact factor: 9.941

2.  In vitro effects of combination chemotherapy on osteoblasts: implications for osteopenia in childhood malignancy.

Authors:  J H Davies; B A J Evans; M E M Jenney; J W Gregory
Journal:  Bone       Date:  2002-08       Impact factor: 4.398

3.  Lack of an association of estrogen receptor alpha gene polymorphisms and transcriptional activity with Alzheimer disease.

Authors:  H Maruyama; H Toji; C R Harrington; K Sasaki; Y Izumi; T Ohnuma; H Arai; M Yasuda; C Tanaka; P C Emson; S Nakamura; H Kawakami
Journal:  Arch Neurol       Date:  2000-02

Review 4.  Genetic regulation of bone mass and susceptibility to osteoporosis.

Authors:  Stuart H Ralston; Benoit de Crombrugghe
Journal:  Genes Dev       Date:  2006-09-15       Impact factor: 11.361

5.  Hypofibrinolysis, thrombophilia, osteonecrosis.

Authors:  C J Glueck; R A Freiberg; R N Fontaine; T Tracy; P Wang
Journal:  Clin Orthop Relat Res       Date:  2001-05       Impact factor: 4.176

Review 6.  Osteonecrosis in children and adolescents with cancer - an adverse effect of systemic therapy.

Authors:  Alessandra Sala; Leonard A Mattano; Ronald D Barr
Journal:  Eur J Cancer       Date:  2006-12-13       Impact factor: 9.162

7.  Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.

Authors:  Anja Möricke; Alfred Reiter; Martin Zimmermann; Helmut Gadner; Martin Stanulla; Michael Dördelmann; Lutz Löning; Rita Beier; Wolf-Dieter Ludwig; Richard Ratei; Jochen Harbott; Joachim Boos; Georg Mann; Felix Niggli; Andreas Feldges; Günter Henze; Karl Welte; Jörn-Dirk Beck; Thomas Klingebiel; Charlotte Niemeyer; Felix Zintl; Udo Bode; Christian Urban; Helmut Wehinger; Dietrich Niethammer; Hansjörg Riehm; Martin Schrappe
Journal:  Blood       Date:  2008-02-19       Impact factor: 22.113

8.  Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts.

Authors:  Takashi Nakamura; Yuuki Imai; Takahiro Matsumoto; Shingo Sato; Kazusane Takeuchi; Katsuhide Igarashi; Yoshifumi Harada; Yoshiaki Azuma; Andree Krust; Yoko Yamamoto; Hiroshi Nishina; Shu Takeda; Hiroshi Takayanagi; Daniel Metzger; Jun Kanno; Kunio Takaoka; T John Martin; Pierre Chambon; Shigeaki Kato
Journal:  Cell       Date:  2007-09-07       Impact factor: 41.582

9.  Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.

Authors:  A Reiter; M Schrappe; W D Ludwig; W Hiddemann; S Sauter; G Henze; M Zimmermann; F Lampert; W Havers; D Niethammer
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113

10.  Large-scale evidence for the effect of the COLIA1 Sp1 polymorphism on osteoporosis outcomes: the GENOMOS study.

Authors:  Stuart H Ralston; André G Uitterlinden; Maria Luisa Brandi; Susana Balcells; Bente L Langdahl; Paul Lips; Roman Lorenc; Barbara Obermayer-Pietsch; Serena Scollen; Mariona Bustamante; Lise Bjerre Husted; Alisoun H Carey; Adolfo Diez-Perez; Alison M Dunning; Alberto Falchetti; Elzbieta Karczmarewicz; Marcin Kruk; Johannes P T M van Leeuwen; Joyce B J van Meurs; Jon Mangion; Fiona E A McGuigan; Leonardo Mellibovsky; Francesca del Monte; Huibert A P Pols; Jonathan Reeve; David M Reid; Wilfried Renner; Fernando Rivadeneira; Natasja M van Schoor; Rachael E Sherlock; John P A Ioannidis
Journal:  PLoS Med       Date:  2006-02-21       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.